Logo Image

Authors

Moffitt Cancer Center
Latest Article

Moffitt Study Suggests Improvements Needed for Patient-Reported Outcome Data in Genitourinary Cancer Clinical Studies

“Our data showed a considerable gap in reporting patient-reported outcomes and in the quality of design and conduct of patient-reported outcomes-related trial endpoints," said Jad Chahoud, MD, MPH.

Ron Southwick
Latest Article

Ascension cyberattack’s impact felt in multiple states

Some Ascension hospitals continue to divert ambulances to other facilities for emergency treatment, but some of the system’s hospitals are accepting all patients.

Lucienne Marie Ide, MD, PhD
Latest Article

Can remote patient monitoring help combat the staffing shortage?

"As more patients become interested in remote patient monitoring and case studies continue to show improved patient outcomes, practices must seek ways to integrate these tools into their workflows," writes Lucienne Marie Ide, MD, PhD.

Scott Webster, MD
Latest Article

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Evan R. Goldfischer, MD, MBA, FACS
Latest Article

Chronic care management in the urologic oncology setting

CCM programs can engage multiple providers to care for patients while reducing in-person visits.

Jeremy D. Sherer, JD
Latest Article

What you need to know about providing telehealth in 2023

Jeremy D. Sherer, JD, explains everything physicians need to know about using telemedicine in their practice in 2023.

Steffanie Robertus
Latest Article

When it comes to urology teaching or learning opportunities, just say yes

"Despite the uncertain times, I am grateful to be a student in the field of medicine, where compassion is one of the traits that defines its practitioners," says PA student Steffanie Robertus.

Melanie McGilloway, NP-C
Latest Article

Comparing Leuprolide Formulations in Advanced Prostate Cancer

In the third article of the series, Melanie McGilloway, NP-C, an advanced practice provider at Genesis Urology in San Diego, discusses the various formulations of leuprolide, a gonadotropin-releasing hormone (GnRH) agonist used for treating advanced prostate cancer.

Vignesh T. Packiam, MD
Latest Article

ASCO GU recap: Vignesh Packiam, MD, on key bladder cancer highlights

Vignesh T. Packiam, MD, reviews several bladder cancer studies from ASCO GU 2026 that he described as clinically meaningful for practicing urologists.

Robert A. Wells
Latest Article

Legislation improves accessibility to mental health programs for clinicians

Congress has taken actions aimed at protecting arrangements in which hospitals and other entities provide bona fide mental health improvement, behavioral health improvement, or maintenance programs to physicians and other clinicians.

Miranda Lankas
Latest Article

Radium-223 is associated with low rates of AEs, treatment discontinuation for bone metastatic CRPC

Of note, 55% of patients received a full course (6 injections) of radium-223 injections, and 67% received 5 of the 6 injections.

Marissa Fiorentino
Latest Article

Cabozantinib plus nivolumab shows encouraging activity in mCRPC

Data from the CANOPY trial showed promising activity and manageable safety with cabozantinib plus nivolumab in mCRPC.

Ashley Gallagher
Latest Article

Mayo study finds dietary habits that may help prevent kidney stones

"Knowing the dietary factors that are most important for preventing kidney stone recurrence can help patients and providers know what to prioritize,” said Andrew Rule, MD.

Antonia DePace
Latest Article

Survey highlights communication gaps with kidney cancer diagnosis and care

“This indicates opportunities to improve communication about diagnosis, psychosocial impacts, and clinical trials, as well as biopsies, physical exercise, and patient engagement,” wrote Rachel H. Giles, PhD, and colleagues.

Gary D. Steinberg, MD
Latest Article

Future of BCG in NMIBC

Panelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the future of first-line treatment be a noninfectious agent that would be easier to develop and include more data.

Alexandria A. Spellman, MD, MS

Spellman is a urology resident at Duke University Medical Center, Durham, North Carolina.

Latest Article

Financial toxicity is a growing concern in urologic oncology

"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.

Lisa Eramo, MA
Latest Article

13 tips to keep your patient data safe from hackers

Here are 13 cybersecurity measures medical practices can take to protect patient data from hackers.

Megan Price, MSN, APRN, FNP-C
Latest Article

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Keith A. Reynolds
Latest Article

Practice Management: Expert coding tips

A physician’s goal is to care for patients, but a key part of being able to provide that care is the eternal quest for payment.

Benjamin J. Martin, MD

Martin is a urologist with Central Ohio Urology Group in Gahanna.

Latest Article

Upper tract urothelial carcinoma case illustrates rapidly changing treatment landscape

Urologists and medical oncologists should collaborate to tailor therapy to the specific needs of the patient.

Vishal Patel, MD
Latest Article

Management of recurrent prostate cancer after focal therapy

Providers must carefully consider treatment options to align with patient preference.

Javier Piraino, DO
Latest Article

Fertility preservation in patients with testicular cancer

"Full discussion of the various fertility preservation options and an understanding of the fertility implications of the various treatment modalities must be understood by patients for them to make optimal decisions for their reproductive futures," write the authors.

Colin Carr
Latest Article

Urology Practice advice: Real estate pitfalls to avoid

Commercial real estate can be one of the highest expenses for health care practices.

Hesham A. Yasin, MD

Yasin is a genitourinary oncology fellow at Vanderbilt University Medical Center, Nashville, Tennessee.

Latest Article

BCG-unresponsive NMIBC: Current evidence and options

Multiple investigational agents have been developed and are being studied.

Justin Wright, MA, MBA
Latest Article

A primer on DNA sequencing for the practicing urologist

Embracing and understanding new and emerging molecular techniques will improve patient outcomes.

Meade Monger
Latest Article

Reining in the administrative burden in health care

Doctors and medical practices are mired in administrative tasks.

Richard Payerchin
Latest Article

Congress to again consider prior authorization reform legislation

The bill has a mass of legislative supporters – at least 41 senators and 127 representatives, along with more than 370 organizations representing patients, physicians, hospitals and Medicare Advantage plans.

Philip Abbosh, MD, PhD
Latest Article

3D bioprinting technology facilitates development of an in vitro biomimetic bladder model

"This exciting and innovative technology has a wide range of possible applications, including tissue engineering, drug development, and precision medicine," write Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.

Nima Almassi, MD

Almassi is a urologist at Glickman Urological & Kidney Institute at the Cleveland Clinic in Ohio.

Latest Article

iRARC adoption is slow but persistent in bladder cancer

"Over the past 10 to 15 years, tremendous efforts have gone into robotic surgical innovation to improve perioperative morbidity for patients with bladder cancer undergoing RC," write Andrew M. Wood, MD, and Nima Almassi, MD.

Denise Myshko
Latest Article

Post-surgery nivolumab boosts disease-free survival in muscle-invasive urothelial carcinoma

Adjuvant treatment with the anti–PD-1 immunotherapy significantly extended the time period after primary treatment in which patients had no signs or symptoms of cancer.